Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy | Zendy

William Lim | Zendy; Frederick Lim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Corticosteroid Management of Coronavirus 2019 (COVID-19) in Patients with Bilateral Adrenalectomy

Author(s) -

William Lim,

Frederick Lim

Publication year - 2021

Publication title -

case reports in infectious diseases

Language(s) - English

Resource type - Journals

eISSN - 2090-6625

pISSN - 2090-6633

DOI - 10.1155/2021/5856600

Subject(s) - medicine , covid-19 , adrenalectomy , corticosteroid , coronavirus , surgery , virology , outbreak , disease , infectious disease (medical specialty)

Since the World Health Organization (WHO) announced coronavirus 2019 (COVID-19) as a pandemic in March 2020, it has been wreaking havoc across countries, affecting people's lives. Corticosteroids have proven to provide a mortality benefit in patients with COVID-19. Although dexamethasone is the most commonly used glucocorticoid and have shown to have mortality benefit in COVID-19 patients, it cannot be used in patients with adrenal insufficiency due to its lack of mineralocorticoid activity. Herein, we discuss a case of challenging corticosteroid management in a patient with COVID-19 complicated by her medical history of bilateral adrenalectomy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research